Sales and Marketing

Showing 15 posts of 11524 posts found.

Personalised leukaemia vaccine shows promise in new trial

December 12, 2016 Sales and Marketing leukaemia

A personalised cancer vaccine has proven to have significant efficacy in the treatment of acute myeloid leukaemia (AML), researchers at …
basel_site

Phase 3 eye drug combo failure for Novartis

December 12, 2016 Research and Development, Sales and Marketing Novartis, ophthotech

Novartis’ has failed in its attempt to expand the applications of its anti-VEGF eye treatment Lucentis (ranibizumab) after the drug …
shutterstock_311949818

Neurodegenerative market to be worth $45 billion by 2022

December 12, 2016 Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative

Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which …

First generic copy of Roche’s Tamiflu hits US market

December 12, 2016 Sales and Marketing Alvogen, Roche, Tamiflu

Drugmaker Alvogen has released the first generic version of Roche’s flu medication Tamiflu (oseltamivir) in the US, where it expects …
shutterstock_38078521

AZ and Lilly come together to battle Alzheimer’s

December 9, 2016 Research and Development, Sales and Marketing AZ, lilly

Pharma titans Eli Lilly and AstraZeneca have announced they are to join forces to co-develop a potential Alzheimer’s treatment, currently …
china_pic

Top Pharmaceutical Markets 2016: China

December 9, 2016 Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing China, market analysis

Originally featured in Pharmafile Autumn 2016, a report from the United States International Trade Administration sheds light on the Chinese …
abbvie_0

European thumbs up for Abbvie leukaemia drug

December 8, 2016 Medical Communications, Sales and Marketing AbbVie, Venclyxto

Abbvie has confirmed its Venclyxto (venetoclax) has been granted marketing authorisation by the European Commission (EC) as a monotherapy for …
sicorbio

Teva embroiled in internal bribery investigation

December 8, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, bribery

Israeli pharmaceutical firm Teva has confirmed it is embroiled in an ongoing internal investigation into allegations of bribery, after the …

Mylan to restructure and slash around 10% of workforce

December 8, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, epipen, job losses

Mylan has submitted a regulatory filing to the Securities and Exchange Commission to announce that it would be potentially cutting …
lisa_anson

AstraZeneca’s Lisa Anson appointed president of ABPI

December 7, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Lisa Anson, current president of AstraZeneca UK & Ireland, has been appointed to the position of president of ABPI. Lisa …
jakob-riis

Novo pledges single-digit cap on drug price hikes

December 7, 2016 Medical Communications, Research and Development, Sales and Marketing Jakob Riis, Novo Nordisk

Novo Nordisk US chief Jakob Riis (pictured) has announced the insulin giant’s commitment to limit its price increases to single-digit …
jake_dupont

CMO of OncoMed Pharma resigns

December 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

OncoMed Pharmaceuticals, a clinical-stage pharmaceutical company, announced that Jakob Dupont has resigned from his positions as the company’s senior vice …
sigurdur_olaffson_teva

CEO of Teva’s Generics Medicines Group steps down

December 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva

Sigurdur Olafsson will step down in the first quarter of 2017 as president and CEO of Teva’s Global Generic Medicines …
jeffrey_eisenberg

Xenetic Biosciences promote Jeffrey Eisenberg from board member to COO

December 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Xenetic

Xenetic Biosciences, a clinical-stage biopharmaceutical company, has announced the appointment of Jeffrey Eisenberg as chief operating officer. Mr. Eisenberg has …
The Gateway to Local Adoption Series

Latest content